Janus Henderson Group PLC raised its position in Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 10.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,606,495 shares of the company's stock after acquiring an additional 352,507 shares during the quarter. Janus Henderson Group PLC owned approximately 12.12% of Eliem Therapeutics worth $18,303,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new stake in shares of Eliem Therapeutics in the 2nd quarter valued at about $134,000. Rhumbline Advisers acquired a new position in Eliem Therapeutics during the second quarter worth approximately $59,000. Dimensional Fund Advisors LP bought a new stake in Eliem Therapeutics in the second quarter valued at approximately $89,000. Renaissance Technologies LLC lifted its position in shares of Eliem Therapeutics by 248.5% in the second quarter. Renaissance Technologies LLC now owns 37,000 shares of the company's stock valued at $263,000 after buying an additional 26,383 shares during the last quarter. Finally, Ally Bridge Group NY LLC bought a new position in shares of Eliem Therapeutics during the 2nd quarter worth approximately $3,555,000. Institutional investors and hedge funds own 69.76% of the company's stock.
Eliem Therapeutics Stock Performance
ELYM traded up $0.11 during trading hours on Friday, reaching $3.02. The company's stock had a trading volume of 116,916 shares, compared to its average volume of 486,688. The company's 50-day moving average is $4.11 and its 200-day moving average is $6.21. Eliem Therapeutics, Inc. has a 52 week low of $2.35 and a 52 week high of $11.55. The firm has a market cap of $89.85 million, a PE ratio of -5.70 and a beta of -0.39.
Eliem Therapeutics Company Profile
(
Free Report)
Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Recommended Stories
Before you consider Eliem Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eliem Therapeutics wasn't on the list.
While Eliem Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.